The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats

Eugene Herman, Alan Knapton, Jun Zhang, Joel Estis, John Todd, Steven E Lipshultz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Imatinib (Imb) is a tyrosine kinase inhibitor with cardiotoxic activity (decreases in left ventricular function and congestive heart failure) in patients. Currently, clinical diagnosis of Imb cardiotoxicity relies primarily on evaluation of left ventricular function, Imb also induces cardiac lesions in rats. Aims: This study, in rats, sought to determine whether monitoring biochemical markers would be a sensitive means to detect Imb-induced changes in cardiomyocyte morphology. Materials and methods: Groups of male Sprague-Dawley rats were dosed orally with 50, 100, 200 mg kg-1 Imb or water daily for 28 days. Tissues and blood samples were collected 24 h after the last dosing. Cardiac biomarkers such as cardiac troponin I (cTnI), cardiac troponin T (cTnT), and fatty acid binding protein 3 (FABP3) were monitored by the Erenna, Elecsys, and Meso Scale immunoassay systems. Results: Imb caused microscopic myocardial lesions (myofibrillar loss, cytoplasmic vacuolization, and necrosis) at all doses as determined by unbiased histopathology analysis. The severity of the alterations was dose-related with mean lesion scores (based on a scale of 0-3) of 1.2 (50 mg kg-1), 2.1 (100 mg kg-1) and 2.9 (200 mg kg-1). However, the increases in cTnI, cTnT, and FABP3 levels were noted primarily in high-dose Imb treated animals. Discussion and conclusion: The occurrence of myocardial alterations in animals without consistent changes in cardiac troponin and FABP3 concentrations raises questions regarding the utility of these biomarkers as early indicators of Imb-induced cardiotoxicity. Due to limited numbers of animals the reasons for this discrepancy could not be determined. e00015

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalPharmacology Research and Perspectives
Volume2
Issue number1
DOIs
StatePublished - Feb 1 2014

Fingerprint

Biomarkers
Serum
Fatty Acid-Binding Proteins
Troponin T
Troponin I
Left Ventricular Function
Troponin
Imatinib Mesylate
Immunoassay
Cardiac Myocytes
Protein-Tyrosine Kinases
Sprague Dawley Rats
Necrosis
Heart Failure
Water

Keywords

  • Cardiac biomarkers
  • Imatinib cardiotoxicity
  • Rats

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neurology

Cite this

The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats. / Herman, Eugene; Knapton, Alan; Zhang, Jun; Estis, Joel; Todd, John; Lipshultz, Steven E.

In: Pharmacology Research and Perspectives, Vol. 2, No. 1, 01.02.2014, p. 1-9.

Research output: Contribution to journalArticle

Herman, Eugene ; Knapton, Alan ; Zhang, Jun ; Estis, Joel ; Todd, John ; Lipshultz, Steven E. / The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats. In: Pharmacology Research and Perspectives. 2014 ; Vol. 2, No. 1. pp. 1-9.
@article{17ed27aaa19d4a4d9b19c9151483a340,
title = "The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats",
abstract = "Background: Imatinib (Imb) is a tyrosine kinase inhibitor with cardiotoxic activity (decreases in left ventricular function and congestive heart failure) in patients. Currently, clinical diagnosis of Imb cardiotoxicity relies primarily on evaluation of left ventricular function, Imb also induces cardiac lesions in rats. Aims: This study, in rats, sought to determine whether monitoring biochemical markers would be a sensitive means to detect Imb-induced changes in cardiomyocyte morphology. Materials and methods: Groups of male Sprague-Dawley rats were dosed orally with 50, 100, 200 mg kg-1 Imb or water daily for 28 days. Tissues and blood samples were collected 24 h after the last dosing. Cardiac biomarkers such as cardiac troponin I (cTnI), cardiac troponin T (cTnT), and fatty acid binding protein 3 (FABP3) were monitored by the Erenna, Elecsys, and Meso Scale immunoassay systems. Results: Imb caused microscopic myocardial lesions (myofibrillar loss, cytoplasmic vacuolization, and necrosis) at all doses as determined by unbiased histopathology analysis. The severity of the alterations was dose-related with mean lesion scores (based on a scale of 0-3) of 1.2 (50 mg kg-1), 2.1 (100 mg kg-1) and 2.9 (200 mg kg-1). However, the increases in cTnI, cTnT, and FABP3 levels were noted primarily in high-dose Imb treated animals. Discussion and conclusion: The occurrence of myocardial alterations in animals without consistent changes in cardiac troponin and FABP3 concentrations raises questions regarding the utility of these biomarkers as early indicators of Imb-induced cardiotoxicity. Due to limited numbers of animals the reasons for this discrepancy could not be determined. e00015",
keywords = "Cardiac biomarkers, Imatinib cardiotoxicity, Rats",
author = "Eugene Herman and Alan Knapton and Jun Zhang and Joel Estis and John Todd and Lipshultz, {Steven E}",
year = "2014",
month = "2",
day = "1",
doi = "10.1002/prp2.15",
language = "English (US)",
volume = "2",
pages = "1--9",
journal = "Pharmacology Research and Perspectives",
issn = "2052-1707",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats

AU - Herman, Eugene

AU - Knapton, Alan

AU - Zhang, Jun

AU - Estis, Joel

AU - Todd, John

AU - Lipshultz, Steven E

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background: Imatinib (Imb) is a tyrosine kinase inhibitor with cardiotoxic activity (decreases in left ventricular function and congestive heart failure) in patients. Currently, clinical diagnosis of Imb cardiotoxicity relies primarily on evaluation of left ventricular function, Imb also induces cardiac lesions in rats. Aims: This study, in rats, sought to determine whether monitoring biochemical markers would be a sensitive means to detect Imb-induced changes in cardiomyocyte morphology. Materials and methods: Groups of male Sprague-Dawley rats were dosed orally with 50, 100, 200 mg kg-1 Imb or water daily for 28 days. Tissues and blood samples were collected 24 h after the last dosing. Cardiac biomarkers such as cardiac troponin I (cTnI), cardiac troponin T (cTnT), and fatty acid binding protein 3 (FABP3) were monitored by the Erenna, Elecsys, and Meso Scale immunoassay systems. Results: Imb caused microscopic myocardial lesions (myofibrillar loss, cytoplasmic vacuolization, and necrosis) at all doses as determined by unbiased histopathology analysis. The severity of the alterations was dose-related with mean lesion scores (based on a scale of 0-3) of 1.2 (50 mg kg-1), 2.1 (100 mg kg-1) and 2.9 (200 mg kg-1). However, the increases in cTnI, cTnT, and FABP3 levels were noted primarily in high-dose Imb treated animals. Discussion and conclusion: The occurrence of myocardial alterations in animals without consistent changes in cardiac troponin and FABP3 concentrations raises questions regarding the utility of these biomarkers as early indicators of Imb-induced cardiotoxicity. Due to limited numbers of animals the reasons for this discrepancy could not be determined. e00015

AB - Background: Imatinib (Imb) is a tyrosine kinase inhibitor with cardiotoxic activity (decreases in left ventricular function and congestive heart failure) in patients. Currently, clinical diagnosis of Imb cardiotoxicity relies primarily on evaluation of left ventricular function, Imb also induces cardiac lesions in rats. Aims: This study, in rats, sought to determine whether monitoring biochemical markers would be a sensitive means to detect Imb-induced changes in cardiomyocyte morphology. Materials and methods: Groups of male Sprague-Dawley rats were dosed orally with 50, 100, 200 mg kg-1 Imb or water daily for 28 days. Tissues and blood samples were collected 24 h after the last dosing. Cardiac biomarkers such as cardiac troponin I (cTnI), cardiac troponin T (cTnT), and fatty acid binding protein 3 (FABP3) were monitored by the Erenna, Elecsys, and Meso Scale immunoassay systems. Results: Imb caused microscopic myocardial lesions (myofibrillar loss, cytoplasmic vacuolization, and necrosis) at all doses as determined by unbiased histopathology analysis. The severity of the alterations was dose-related with mean lesion scores (based on a scale of 0-3) of 1.2 (50 mg kg-1), 2.1 (100 mg kg-1) and 2.9 (200 mg kg-1). However, the increases in cTnI, cTnT, and FABP3 levels were noted primarily in high-dose Imb treated animals. Discussion and conclusion: The occurrence of myocardial alterations in animals without consistent changes in cardiac troponin and FABP3 concentrations raises questions regarding the utility of these biomarkers as early indicators of Imb-induced cardiotoxicity. Due to limited numbers of animals the reasons for this discrepancy could not be determined. e00015

KW - Cardiac biomarkers

KW - Imatinib cardiotoxicity

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=85017068024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017068024&partnerID=8YFLogxK

U2 - 10.1002/prp2.15

DO - 10.1002/prp2.15

M3 - Article

AN - SCOPUS:85017068024

VL - 2

SP - 1

EP - 9

JO - Pharmacology Research and Perspectives

JF - Pharmacology Research and Perspectives

SN - 2052-1707

IS - 1

ER -